· 20h
Johnson & Johnson Tops Q4 EPS Forecasts
· 21h
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
· 22h · on MSN
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
· 3h
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
· 16h
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
· 8h · on MSN
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
Some results have been hidden because they may be inaccessible to you
Show inaccessible results